Trevena (TRVN) Competitors $1.01 0.00 (0.00%) As of 06/11/2025 03:20 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock TRVN vs. SONN, JAGX, PCSA, ARTL, ELAB, SPRC, PPBT, ONVO, NBY, and VIVSShould you be buying Trevena stock or one of its competitors? The main competitors of Trevena include Sonnet BioTherapeutics (SONN), Jaguar Health (JAGX), Processa Pharmaceuticals (PCSA), Artelo Biosciences (ARTL), Elevai Labs (ELAB), SciSparc (SPRC), Purple Biotech (PPBT), Organovo (ONVO), NovaBay Pharmaceuticals (NBY), and Organovo (VIVS). These companies are all part of the "pharmaceutical products" industry. Trevena vs. Its Competitors Sonnet BioTherapeutics Jaguar Health Processa Pharmaceuticals Artelo Biosciences Elevai Labs SciSparc Purple Biotech Organovo NovaBay Pharmaceuticals Organovo Trevena (NASDAQ:TRVN) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Is TRVN or SONN more profitable? Trevena's return on equity of 0.00% beat Sonnet BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TrevenaN/A N/A -119.55% Sonnet BioTherapeutics N/A -408.93%-174.13% Do insiders & institutionals hold more shares of TRVN or SONN? 13.6% of Trevena shares are held by institutional investors. Comparatively, 9.4% of Sonnet BioTherapeutics shares are held by institutional investors. 2.7% of Trevena shares are held by company insiders. Comparatively, 2.0% of Sonnet BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, TRVN or SONN? Trevena has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Sonnet BioTherapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Does the media refer more to TRVN or SONN? In the previous week, Sonnet BioTherapeutics had 3 more articles in the media than Trevena. MarketBeat recorded 3 mentions for Sonnet BioTherapeutics and 0 mentions for Trevena. Sonnet BioTherapeutics' average media sentiment score of 0.96 beat Trevena's score of 0.00 indicating that Sonnet BioTherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Trevena Neutral Sonnet BioTherapeutics Positive Does the MarketBeat Community prefer TRVN or SONN? Trevena received 594 more outperform votes than Sonnet BioTherapeutics when rated by MarketBeat users. However, 84.62% of users gave Sonnet BioTherapeutics an outperform vote while only 68.14% of users gave Trevena an outperform vote. CompanyUnderperformOutperformTrevenaOutperform Votes61668.14% Underperform Votes28831.86% Sonnet BioTherapeuticsOutperform Votes2284.62% Underperform Votes415.38% Which has preferable earnings and valuation, TRVN or SONN? Sonnet BioTherapeutics has higher revenue and earnings than Trevena. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevena$443K2.19-$40.29M-$47.04-0.02Sonnet BioTherapeutics$1M3.70-$7.44MN/AN/A Do analysts rate TRVN or SONN? Trevena presently has a consensus price target of $5.00, suggesting a potential upside of 395.05%. Sonnet BioTherapeutics has a consensus price target of $20.00, suggesting a potential upside of 1,609.26%. Given Sonnet BioTherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sonnet BioTherapeutics is more favorable than Trevena.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Sonnet BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummarySonnet BioTherapeutics beats Trevena on 10 of the 15 factors compared between the two stocks. Get Trevena News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVN vs. The Competition Export to ExcelMetricTrevenaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$969K$6.92B$5.60B$8.61BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.028.8427.2219.97Price / Sales2.19255.17408.95152.58Price / CashN/A65.8538.2534.64Price / Book-0.096.587.114.68Net Income-$40.29M$144.20M$3.24B$248.05M7 Day Performance-3.99%3.32%2.47%2.40%1 Month Performance-14.41%10.53%8.66%6.14%1 Year Performance-89.83%3.63%31.22%13.62% Trevena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVNTrevena2.1193 of 5 stars$1.01flat$5.00+395.0%-89.9%$969K$443K-0.0240Gap UpSONNSonnet BioTherapeutics2.8313 of 5 stars$1.22-2.2%$20.00+1,535.3%-37.4%$3.87M$1M0.0010News CoverageShort Interest ↓JAGXJaguar Health2.5783 of 5 stars$3.80-6.4%$60.00+1,478.9%-95.8%$3.87M$11.55M0.0050Positive NewsHigh Trading VolumePCSAProcessa Pharmaceuticals3.1146 of 5 stars$0.32+8.0%$6.00+1,747.9%-77.8%$3.86MN/A-0.1020ARTLArtelo Biosciences2.8195 of 5 stars$1.11-0.9%$5.50+395.5%-13.7%$3.64MN/A-0.395Analyst DowngradeStock SplitShort Interest ↓ELABElevai Labs1.105 of 5 stars$2.64+21.7%N/A-99.7%$3.63M$2.45M-0.0418Gap UpHigh Trading VolumeSPRCSciSparc1.0243 of 5 stars$0.33+4.2%N/A-63.8%$3.52M$1.31M0.004Short Interest ↓Gap DownPPBTPurple Biotech2.6921 of 5 stars$2.61-0.4%$33.00+1,164.4%N/A$3.47MN/A-0.3020ONVOOrganovoN/AN/AN/AN/A$3.47M$122K-2.4020Gap UpNBYNovaBay PharmaceuticalsN/A$0.59+2.5%$0.85+43.0%-78.7%$3.46M$9.78M-0.0130VIVSOrganovoN/A$1.82-1.1%N/AN/A$3.45M$122K-0.1820Gap Down Related Companies and Tools Related Companies SONN Alternatives JAGX Alternatives PCSA Alternatives ARTL Alternatives ELAB Alternatives SPRC Alternatives PPBT Alternatives ONVO Alternatives NBY Alternatives VIVS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRVN) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevena, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
